SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: SemiBull who wrote (1185)3/19/2002 7:46:13 PM
From: SemiBull  Read Replies (2) of 1298
 
Transkaryotic In Settlement On Gene Therapy Patent

CAMBRIDGE, Mass. -(Dow Jones)- Transkaryotic Therapies (NasdaqNM: TKTX - news) Inc. (TKTX) reached a settlement on gene therapy patent interferences involving Novartis AG's (NVS) Genetic Therapy Inc. unit, Roche Holding AG's (RHHBY) Syntex and Cell Genesys (NasdaqNM: CEGE - news) Inc. (CEGE)

In a press release Monday, Transkaryotic said the settlements allow it to practice its non-viral ex vivo gene therapy under royalty-free licenses in the event that any broad claims to gene therapy survive the original interference or issue in any of the pending interferences.

The original interference, declared in 1996, initially involved a Transkaryotic patent application with claims to non-viral ex vivo gene therapy, and a U.S. patent issued to the National Institutes of Health with broad claims to ex vivo gene therapy.

The patent was licensed to Genetic Therapy Inc., although Cell Genesys and Syntex also became parties in the interference based on their gene therapy patent applications.

In Transkaryotic Therapy, a small sample of a patient's cells is removed and sent to the company's manufacturing facility where the cells are genetically- engineered to produce the desired protein for extended periods of time. After the cells and the protein have been tested to ensure both safety and functionality, an appropriate number of genetically-engineered cells is returned to the physician and injected back into the patient, the company said.

The company's lead gene therapy program is focused on the delivery of Factor VIII in patients with hemophilia A.

-Thomas Gryta; Dow Jones Newswires; 201-938-5400
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News